表紙:特発性肺線維症 (IPF):疫学予測 (~2029年)
市場調査レポート
商品コード
961733

特発性肺線維症 (IPF):疫学予測 (~2029年)

Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.72円
特発性肺線維症 (IPF):疫学予測 (~2029年)
出版日: 2020年09月15日
発行: GlobalData
ページ情報: 英文
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場における特発性肺線維症 (IPF) の患者総数 (発症者数・有病者数) は、2019年の201,698人から、2029年には237,113人へ増加し、予測期間中は1.76%のAGRが見込まれています。IPFは男性でより一般的であり、IPFの発症者数と有病者数は通常年齢が上がるにつれて増加します。

当レポートでは、特発性肺線維症 (IPF)について調査し、疾病の概要、患者背景、主要7カ国における特発性肺線維症 (IPF)の発症者数・有病者数の予測(今後10年間分)、市場の成長機会などを包括的にまとめています。

目次

第1章 目次

第2章 特発性肺線維症:エグゼクティブサマリー

  • 促進要因
  • 関連レポート
  • 今後のレポート

第3章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
  • 世界および歴史的動向
  • 調査手法
    • ソース
    • 予測の前提条件と方法
  • IPFの疫学予測
    • IPFの発症者数
    • IPFの発症者数:性別
    • IPFの発症者数:年齢別
    • IPFの有病者数
    • IPFの有病者数:性別
    • IPFの有病者数:年齢別
    • IPFの有病者数:重症度別
    • IPFの有病者数:併存疾患別
    • IPFの有病者数の総計
  • 議論
    • 疫学予測の洞察
    • 新型コロナウイルス感染症(COVID-19)の影響
    • 分析の制限事項
    • 分析の強み

第4章 付録

図表

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for IPF
  • Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages ≥18 Years, 2019
  • Table 5: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2020

List of Figures

List of Figures

  • Figure 1: 7MM, Diagnosed Incident Cases of IPF, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 7MM, Diagnosed Prevalent Cases of IPF, Both Sexes, Ages ≥18 Years, 2019 and 2029
  • Figure 3: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages ≥18 Years, 2019
  • Figure 4: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 5: 7MM, Total Prevalence of IPF, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
  • Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
  • Figure 9: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 11: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 12: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages ≥18 Years, 2019
  • Figure 14: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
  • Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 16: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages ≥18 Years, 2019
目次
Product Code: GDHCER249-20

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease and is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs. This condition occurs when the lung tissue becomes thick and stiff for unknown reasons. Over time, breathing becomes difficult due to fibrosis caused by permanent scarring in the lungs (NHLBI, 2019). IPF is associated with a poor prognosis, with a median survival of three to five years (Raghu et al., 2011). There is currently no cure for IPF. However, certain medicines may slow the progression of IPF, which may extend the lifespan and improve the quality of life for people who have the disease (NHLBI, 2019).

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals to build the forecast. GlobalData epidemiologists used sources that confirmed IPF cases through both a biopsy of the lung and high-resolution computed tomography (HRCT). The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent (total and diagnosed) cases of IPF in the 7MM, segmented by age, sex, severity, and comorbidities.

The following data describes epidemiology of IPF. In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of IPF from 28,301 cases in 2019 to 32,997 cases in 2019, at an AGR of 1.66% over the forecast period. The diagnosed prevalent cases of IPF in the 7MM will increase from 130,822 cases in 2019 to 153,747 cases in 2029, at an AGR of 1.75% over the forecast period. The total prevalent cases of IPF in the 7MM will increase from 201,698 cases in 2019 to 237,113 cases in 2029, at an AGR of 1.76% over the forecast period. IPF is more common in men, and the incidence and prevalence of IPF typically increases with advancing age. These trends are reflected in GlobalData's forecast for the diagnosed incident and prevalent (total and diagnosed) cases for the 7MM.

Scope

  • The Idiopathic Pulmonary Fibrosis (IPF) Epidemiology Report provides an overview of the risk factors and global trends of IPF in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident and prevalent cases of IPF (total and diagnosed) segmented by sex and age (ages ≥18 years). The prevalent cases of IPF (total and diagnosed) are also segmented by severity (mild, moderate, and severe), and comorbidities (pulmonary hypertension, chronic obstructive pulmonary disease, lung cancer, sleep apnea, pulmonary embolism, gastro-esophageal reflux disease, and depression). In addition, the model corresponding to this report includes age- and sex-specific mortality for IPF for ages 18 years and older.
  • The IPF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Idiopathic Pulmonary Fibrosis Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global IPF market.
  • Quantify patient populations in the global IPF market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IPF therapeutics in each of the markets covered.
  • Understand magnitude of IPF population by severity at diagnosis.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Idiopathic Pulmonary Fibrosis: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for IPF (2019-2029)
    • 3.5.1 Diagnosed Incident Cases of IPF
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of IPF
    • 3.5.3 Age-Specific Diagnosed Incident Cases of IPF
    • 3.5.4 Diagnosed Prevalent Cases of IPF
    • 3.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
    • 3.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
    • 3.5.7 Diagnosed Prevalent Cases of IPF by Severity
    • 3.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
    • 3.5.9 Total Prevalent Cases of IPF
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer